Author

Stephanie P. Vo

University of MinnesotaORCID 0000-0002-2005-2372Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:metagenomics· 1 Assay:proteomics· 1

Frequent Co-Authors

Anthony D. BaughniD· 2 shared Courtney C. AldrichiD· 2 shared Lev OstreriD· 2 shared Ziyi JiaiD· 2 shared Betelhem Tatek· 1 shared Camilla Folvar· 1 shared Dirk SchnappingeriD· 1 shared Donald R. RonningiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Anthony D. BaughnORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Validating Conditionally Essential Targets: Discovery of the First Orally Effective Biotin Inhibitor against MycobacteriumTuberculosis

Qiang Liu, Joshua B. Wallach, Yahani P. Jayasinghe, Mark R. Sullivan, Julianna Proietto, Suyapa Rodriguez, Stephanie P. Vo, Helena I. Boshoff, Ziyi Jia, Camilla Folvar, Betelhem Tatek, Firat Kaya, Lev Ostrer, Kritee Mehdiratta, Rui Shi, , Courtney C. Aldrich

The paper develops an orally effective biotin inhibitor, C48, against Mycobacterium tuberculosis, demonstrating in vivo efficacy in a low-biotin mouse model.

bioRxiv · Sep 24, 2025 · PreprintMicrobiology

Mechanism of the Dual Action Self-Potentiating Antitubercular Drug Morphazinamide

Lev Ostrer, Taylor A. Crooks, Michael D. Howe, Stephanie P. Vo, Ziyi Jia, Pooja V. Hegde, Nathan A. Schacht, Courtney C. Aldrich, Anthony D. Baughn

This study identifies a dual mechanism of action for morphazinamide, a more potent pyrazinamide analog, showing it kills Mycobacterium tuberculosis through coenzyme A disruption and aldehyde release, which also bypasses resistance.

PNAS Nexus · Jul 29, 2025Peer-reviewedMicrobiology